<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04922151</url>
  </required_header>
  <id_info>
    <org_study_id>SSGJ-601-pmCNV-II-01</org_study_id>
    <nct_id>NCT04922151</nct_id>
  </id_info>
  <brief_title>601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)</brief_title>
  <official_title>A Randomized, Double Masked, Multicenter, Phase II Study Assessing the Safety and Efficacy of 601 Versus Ranibizumab in Patients With Visual Impairment Due to Pathological Myopic Choroidal Neovascularization (pmCNV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF&#xD;
      monoclonal antibody in patients with visual impairment due to pmCNV&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following a 14-day maximum screening period, patients will be randomized and followed for&#xD;
      approximately 36 weeks. Treatment visits will be scheduled in 4-week intervals. After 1&#xD;
      initial injection of 601 or ranibizumab (loading phase), subjects will enter an&#xD;
      individualized flexible treatment (IFT) phase (week 4 to week 32). During the IFT phase, an&#xD;
      assessment of disease stability will be performed at each monthly visit and subjects will&#xD;
      receive either an injection or not. Safety and efficacy outcomes will continue to be&#xD;
      evaluated up to a period of 36 weeks unless the patient is withdrawn or discontinues the&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in best-corrected visual acuity (BCVA) at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Assessed with ETDRS visual acuity testing charts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Change of BCVA on each visit compared to baseline.</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>Assessed with ETDRS visual acuity testing charts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in central retina thickness (CRT) on each visit</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>OCT (optical coherence tomography) was used to assess central retina thickness (CRT) representing the average retinal thickness of the central 1 mm diameter subfield around the foveal center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of study eyes with a gain ≥ 5, 10 and 15 letters in BCVA on each visit compared to baseline</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>Assessed with ETDRS visual acuity testing charts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of injections from Week 4 to Week 36</measure>
    <time_frame>Week 4 to Week 36</time_frame>
    <description>Number of administered injections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ocular and non-ocular AEs up to Week 36</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>Incidence of ocular and non-ocular AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of 601</measure>
    <time_frame>Baseline, Week 4, Week 12, Week 24 and Week 36.</time_frame>
    <description>Steady-state blood concentrations of 601</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of VEGF</measure>
    <time_frame>Baseline, Week 4, Week 12, Week 24 and Week 36.</time_frame>
    <description>Detection of VEGF blood concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of 601</measure>
    <time_frame>Baseline, Week 4, Week 12, Week 24 and Week 36.</time_frame>
    <description>Detection of blood Anti-drug antibody (ADA) status. If ADA was positive, Neutralization antibody (Nab) will be tested</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pathological Myopic Choroidal Neovascularization</condition>
  <arm_group>
    <arm_group_label>group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>601 1.25mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ranibizuman 0.5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>601</intervention_name>
    <description>intravitreal recombinant humanized anti-VEGF monoclonal antibody</description>
    <arm_group_label>group I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>intravitreal recombinant humanized anti-VEGF monoclonal antibody</description>
    <arm_group_label>group II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sign informed consent form and willing to be visited at the time specified in the&#xD;
             trial&#xD;
&#xD;
          -  Male or Female, at least 18 years of age&#xD;
&#xD;
          -  The study eye must meet the following criteria&#xD;
&#xD;
          -  Diagnosed with active choroidal neovascularization secondary to pathological myopia&#xD;
&#xD;
          -  BCVA score between 78 and 24 letters, inclusive, using ETDRS visual acuity testing&#xD;
             charts (approximate Snellen equivalent of 20/32 to 20/320)&#xD;
&#xD;
          -  No optometric media opacity and pupil abnormal&#xD;
&#xD;
          -  BCVA score ≥ 34 letters in the fellow eye, using ETDRS visual acuity testing charts&#xD;
             (approximate Snellen equivalent of 20/200)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CNV secondary to other causes (except pathological myopia), such as&#xD;
             neovascularage-related macular degeneration (nAMD), polypoid choroidal vascular&#xD;
             disease (PCV), and secondary injury&#xD;
&#xD;
          -  The fovea has fibrosis and organochemical foci or scar or atrophy that obviously&#xD;
             involves the fovea and causes irreversible vision loss;&#xD;
&#xD;
          -  Previous use of intraocular or periocular steroids within 3 months prior to baseline,&#xD;
             or previous use of dexamethasone intravitreal implant within 6 months prior to&#xD;
             enrollment;&#xD;
&#xD;
          -  PDT, Macular laser photocoagulation (focal/grid), vitrectomy or keratoplasty in the&#xD;
             study eye at any time prior to baseline. Panretinal laser photocoagulation，YAG laser&#xD;
             treatment or any other ocular surgeries (e.g. cataract surgery ) in the study eye&#xD;
             within 3 months prior to the baseline&#xD;
&#xD;
          -  Aphakia (except IOL) or posterior capsular defect (except YAG posterior capsulotomy&#xD;
             after intraocular lens implantation surgery)&#xD;
&#xD;
        For Any Eye:&#xD;
&#xD;
          -  Any eye has active ocular infections (e.g. blepharitis, conjunctivitis, keratitis,&#xD;
             scleritis, uveitis, endophthalmitis)&#xD;
&#xD;
          -  History of intravitreal use of anti-VEGF drugs (e.g.&#xD;
             ranibizumab，bevacizumab，aflibercept, conbercept, etc.) in any eye within 3 months&#xD;
             prior to baseline&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          -  History of allergy to fluorescein sodium and allergies to protein products for&#xD;
             treatment or diagnosis&#xD;
&#xD;
          -  History of stroke (cerebrovascular accident), myocardial infarction, active&#xD;
             disseminated intravascular coagulation or pronounced bleeding tendency in the past 6&#xD;
             months prior to baseline&#xD;
&#xD;
          -  Diagnosed systemic immune diseases (e.g. ankylosing spondylitis, systemic lupus&#xD;
             erythematosus, Behcet's disease, rheumatoid arthritis, scleroderma etc.)&#xD;
&#xD;
          -  any uncontrolled clinical problem (e.g. AIDS, active hepatitis, serious mental,&#xD;
             neurological, cardiovascular, respiratory and other systemic diseases or malignant&#xD;
             tumors, etc.). Malignant tumors with no metastasis or recurrence within 5 years or&#xD;
             cancers in situ cancers are not excluded.&#xD;
&#xD;
          -  History of system use of anti-VEGF drugs (e.g. bevacizumab) within 3 months prior to&#xD;
             baseline&#xD;
&#xD;
        Laboratory Exclusion Criteria:&#xD;
&#xD;
          -  Liver dysfunction (ALT or AST is 2 times higher than the upper limit of normal value&#xD;
             in the local laboratory). Renal function impairment (Cr is 1.5 times higher than the&#xD;
             upper limit of normal values in the local laboratory)&#xD;
&#xD;
          -  Abnormal coagulation function (prothrombin time &gt;= the upper limit of normal value for&#xD;
             3 seconds) and activated partial thromboplastin time &gt;= the upper limit of normal&#xD;
             value for 10 seconds);&#xD;
&#xD;
        Other Exclusion Criteria:&#xD;
&#xD;
          -  Non-use of effective contraception during childbearing age (except for women with&#xD;
             spontaneous admonishment of more than 12 months)&#xD;
&#xD;
          -  Pregnancy and lactation women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YouXin Chen, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YouXin Chen, PhD</last_name>
    <phone>+86-010-65296358</phone>
    <email>Chenyouxinpumch@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>BeiJing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YouXin Chen, PhD</last_name>
    </contact>
    <investigator>
      <last_name>YouXin Chen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 4, 2021</study_first_submitted>
  <study_first_submitted_qc>June 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VEGF; pmCNV; antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Myopia</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

